Pharmacokinetic and Pharmacodynamic Effect of LY2189265 on Lisinopril in Subjects With Hypertension and Metoprolol in Healthy Subjects

Registration

Registration

NCT01324388

Study type

INTERVENTIONAL

Allocation

RANDOMIZED

Phase

PHASE1

Masking

SINGLE

Status

COMPLETED

Enrollment

51

Start

2011-03

Primary completion

2011-08

Lead sponsor

Eli Lilly and Company

Conditions

Diabetes Mellitus, Type 2

Interventions

BIOLOGICAL:LY2189265; DRUG:Metoprolol; DRUG:Lisinopril; DRUG:Placebo

Results posted

TRUE

Secondary identifiers

OTHER:H9X-MC-GBCO

Registered primary outcomes

• Pharmacokinetics, Area Under the Concentration Curve (AUC) of Lisinopril [Day -1, Day 3, Day 24 of Part 1]
• Pharmacokinetics, Maximum Concentration (Cmax) of Lisinopril [Day -1, Day 3, Day 24 in Part 1]
• Mean, 24-hour Heart Rate (Collected by Ambulatory Blood Pressure Monitoring [ABPM]) in Response to Co-administration of LY2189265 and Metoprolol [Day -1, Day 4, Day 7 of Treatment 2 in Part 2]
• Mean, 24-hour Blood Pressure (Collected by Ambulatory Blood Pressure Monitoring [ABPM]) in Response to Co-administration of LY2189265 and Metoprolol [Day -1, Day 4, Day 7 of Treatment 2 in Part 2]